Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy [0.03%]
Mengchao An,Jiayao Yan,Baorui Liu et al.
Mengchao An et al.
Solid tumors remain a formidable challenge in cancer therapy, often evading even the most advanced immunotherapies. Natural killer (NK) cells, cytotoxic innate lymphocytes capable of recognizing and eliminating tumor cells without prior ant...
Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma [0.03%]
Yun Seong Jeong,Ji-Hyun Shin,Soo Mi Kim et al.
Yun Seong Jeong et al.
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. Although the hypoxia-inducible factor 1A (HIF1A) pathway is crucial in HCC progression, its regulatory mechanisms remain unclear as mutations i...
The Roles of Protein S-Palmitoylation in Cancers: From Dynamic Modulation to Therapeutic Potential [0.03%]
Haonan Zheng,Xiaoyu Sun,Yang Gao et al.
Haonan Zheng et al.
Protein S-palmitoylation is a highly conserved posttranslational lipid modification that occurs on cysteine residues and critically influences protein maturation, subcellular localization, trafficking, and stability. Owing to its unique rev...
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study [0.03%]
Sheng Yang,Yanqiu Zhao,Meili Sun et al.
Sheng Yang et al.
Background: From 2019 July 15 to 2022 February 14, the REZOR study enrolled 369 treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations (exon 19 deletion or L858R mutation). Patients...
TOPK Suppresses the CD8+ T Cell Antitumor Immunity via Modulation of IRF5 Expression [0.03%]
通过调节IRF5的表达水平，TOPK抑制CD8⁺T细胞的抗肿瘤免疫反应
Nianke Zang,Jinfeng Gan,Ye Chen et al.
Nianke Zang et al.
Background: T-LAK cell-originated protein kinase (TOPK), a serine/threonine kinase, is aberrantly overexpressed in human tumors and promotes malignant proliferation. Melanoma is a highly immunogenic tumor in which CD8+ T cell-mediated cytot...
CEBPB-Regulated Gastric Cell Plasticity Promotes Liver Metastasis of Gastric Cancer [0.03%]
CEBPB调节的胃细胞 plasticity促进胃癌肝转移
Zhixiang Zuo,Jiaqi Liang,Li-Na He et al.
Zhixiang Zuo et al.
Background: Liver metastasis represents the most common distant dissemination in gastric cancer (GC) but persists as a challenging condition to manage, and its driving molecular mechanisms remain poorly understood. This study aimed to uncov...
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort [0.03%]
免疫肉瘤II期主试验：Sunitinib和Nivolumab联合治疗透明细胞肉瘤患者的II期临床研究
Javier Martin-Broto,Sandra J Strauss,Emanuela Palmerini et al.
Javier Martin-Broto et al.
Background: Clear cell sarcoma (CCS) is an ultrarare sarcoma driven by a specific chromosomal translocation, most commonly the EWS RNA binding protein 1-activating transcription factor 1 fusion (EWSR1::ATF1), for which chemotherapy shows li...
Revolutionary ctDNA-Guided Therapy Adaptation in ESR1-Mutated Advanced Breast Cancer: Insights from the Initial SERENA-6 Trial [0.03%]
基于ctDNA指导的治疗方案调整在ESR1突变晚期乳腺癌中的初步SERENA-6研究結果及启示
Lulu Yang,Ning Zhu,Ying Yuan et al.
Lulu Yang et al.
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial [0.03%]
替拉贝替尼治疗复发胶质母细胞瘤或继发胶质母细胞瘤III期临床试验：IDH突变的间变性astrocytoma, 4级及IDH野生型PTPRZ1-MET融合基因患者
Zhaoshi Bao,Yake Xue,Yanhui Liu et al.
Zhaoshi Bao et al.
Background: High-grade gliomas, including isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH wild-type glioblastoma, have a poor prognosis and limited treatment options. The PTPRZ1-MET (ZM) fusion gene is a potential therapeutic targ...
Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma [0.03%]
异位性CD11c驱动SMAD3介导的食管鳞癌异常抗原呈递和上皮间质转化
Han Liao,Xuan Zhao,Liping Chen et al.
Han Liao et al.
Background: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive cancer with a poor prognosis, where immune evasion plays a central role in tumor progression and resistance to therapy. The underlying mechanisms of tumor-stroma i...